Selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) are infectionprevention measures used in the treatment of some patients in intensive care, but reported eff ects on patient outcome are confl icting.
Commentary
Intensive care unit (ICU)-acquired infections, such as ventilator-associated pneumonia (VAP), are common, costly, and associated with increased morbidity and mortality. Prophylactic antibiotic regimens, such as selective decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination (SOD), have the potential to reduce VAP and mortality rates. SDD consists of intravenous antibiotic administration coupled with topical application in the oropharynx and stomach. SOD, on the other hand, consists solely of topical antibiotic application to the oropharynx. Reductions in the incidence of respiratory tract infections have been demonstrated with both SDD and SOD. Proof of mortality reduction with these techniques is lacking due to the relatively small size of prior studies. Meta-analyses suggest that SDD, but not SOD, reduces mortality [2] [3] [4] [5] . Enthusiasm regarding use of either of these techniques has been tempered by the very real threat of increased selection of antibiotic-resistant pathogens.
To determined the eff ectiveness of SDD and SOD in intensive care unit patients, de Smet and colleagues conducted a large, multicenter, cluster randomized trial of these modalities verses standard care in 5939 adult ICU patients, 92% of which were mechanically ventilated for more than 48 hours, with the remaining subjects anticipated to stay in the ICU for more than 72 hours. Despite the large size of the study, randomization failed to balance important baseline patient characteristics, such as severity of illness, presence of mechanical ventilation, and post-operative status. Due to these imbalances and the need to account for potential cluster eff ects, the main results of the study are those of a random-eff ects logistic regression model. Crude 28-day mortality rates did not diff er between standard care, SOD, and SDD groups (27.5%, 26.6%, and 26.9%, p=0.78). After adjusting for baseline diff erences, however, both SOD and SDD were associated with lower odds of death as compared to standard care, with odds ratios of 0.86 (p=0.045) and 0.83 (p=0.02), respectively. Based on the models, SOD was estimated to reduce 28-day mortality by 2.9% (absolute risk reduction) and SDD by 3.5%, with corresponding numbers need to treat of 34 and 29. Th ere were no shortterm increases in bacterial resistance in surveillance cultures or in the detection of C. diffi cile toxin.
Th is is the largest study to date to examine the use of SDD and SOD in the ICU. Unfortunately, the failure of randomization to balance baseline characteristics and the lack of a signifi cant diff erence in crude mortality rates is cause for concern. True, regression analysis was used to adjust for known diff erences in baseline characteristics, but what of those that were unmeasured, and therefore, unknown? Perhaps more concerning are issues of generalizablity. Th e study population in the Netherlands is quite diff erent in terms of microbiologic characteristics when compared to other parts of the world, especially the United States. For instance, in this study of 5939 patients there were only 29 patients with C. diffi cile toxin, 8 patients with vancomycin-resistant enterococci, and no patients with methicillin-resistant S. aureus, which is drastically diff erent from many ICUs in the rest of the world. Th ough there were no short-term increases in bac terial resistance in this study, the eff ect of these prophylactic regimens on long-term resistance is unknown. More recently, the same group of authors reported the ecological eff ects of the SOD and SDD regimens used in this study on resistant gram-negative bacterial colonization in study ICUs [6] . Th ey found that SOD and SDD had marked eff ects on the bacterial ecology in an ICU, with rising ceftazidime resistance prevalence rates in the respiratory tract during the intervention and a considerable rebound eff ect of ceftazidime resistance in the intestinal tract after discontinuation of SDD. Other studies suggest that in settings with high levels of endemic, multidrug-resistant gram-negative bacteria [7, 8] or methicillin-resistant S. aureus [9] , SDD is associated with increased selection of such pathogens. Importantly, one of the oral antimicrobials used in the study, colistin, is one of the last resort antibiotics for multidrug resistant Pseudomonas aeruginosa and Acineto bacter [3] .
Recommendation
Since there were similar mortality reductions with both SDD and SOD, SOD may be the preferred modality, at least in low-resistance settings since it avoids routinely exposing patients to intravenous antibiotics. However, in high-resistance settings it is not clear whether either modality should be used due to concerns over emerging resistance and the lack of adequately powered studies demonstrating a morality benefi t in these settings. In high-resistance settings, standard VAP precautions [10] , such as head-of-bed elevation, sedation interruption, and spontaneous breathing trials, and oral antiseptics, such as chlorhexidine [2] , may be better options.
